LYRA THERAPEUTICS INC. - COMMON STOCK

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 ноя 2024 16:01:58 Источник Nasdaq GlobeNewswire

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

15 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

27 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

14 авг 2024 16:01:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

21 май 2024 09:14:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

06 май 2024 07:59:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

30 апр 2024 16:04:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

26 апр 2024 16:51:11 Источник Nasdaq GlobeNewswire

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

21 мар 2024 16:01:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 мар 2024 16:01:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 ноя 2023 16:01:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics to Participate in Upcoming Investor Conferences

07 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer

16 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

12 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics to Participate in Upcoming Investor Conferences

06 сен 2023 15:00:28 Источник Nasdaq GlobeNewswire

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

29 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

08 авг 2023 16:01:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

13 июл 2023 07:30:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

02 июн 2023 16:01:00 Источник Nasdaq GlobeNewswire

Lyra Therapeutics to Present at Jefferies Healthcare Conference

02 июн 2023 07:30:00 Источник Nasdaq GlobeNewswire